Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

References

• Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a break- point cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–914. doi: 10.1016/0092-8674(91)90397-H
   PubMed Web of Science ®Google Scholar
• Pieretti M, Zhang F, Fu YH, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–822. doi: 10.1016/0092-8674(91)90125-I
   PubMed Web of Science ®Google Scholar
• Hunter J, Rivero‐Arias O, Angelov A, et al. Epidemiology of fragile X syndrome: a systematic review and meta‐analysis. Am J Med Genet A. 2014;164(7):1648–1658. doi: 10.1002/ajmg.a.36511
   Web of Science ®Google Scholar
• Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10(1):31–41. doi:10.1002/mrdd.20006
   PubMedGoogle Scholar
• De Vries BB, Jansen CC, Duits AA, et al. Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family. J Med Genet. 1996;33(12):1007–1010. doi: 10.1136/jmg.33.12.1007
   PubMed Web of Science ®Google Scholar
• Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378–390. doi: 10.1542/peds.2008-0317
   PubMed Web of Science ®Google Scholar
• Hardiman RL, McGill P. How common are challenging behaviors amongst individuals with fragile X syndrome? A systematic review. Res Dev Disabil. 2018;76:99–109. doi:10.1016/j.ridd.2018.02.020
   PubMed Web of Science ®Google Scholar
• Cordeiro L, Ballinger E, Hagerman R, et al. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3(1):57–67. doi:10.1007/s11689-010-9067-y
   PubMed Web of Science ®Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. Carl Heneghan, “explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of Evidence (background document)”. Oxford Centre For Evidence-Based. 2011/Medicine. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence/OxfordCentreforEvidence-BasedMedicine:LevelsofEvidence(March2009)—CentreforEvidence-BasedMedicine(CEBM),UniversityofOxford.
   Google Scholar
• Hagerman RJ, Jackson AW, Levitas A, et al. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet A. 1986;23(1‐2):241–262. doi: 10.1002/ajmg.1320230119
   Web of Science ®Google Scholar
• Dunn LM, Dunn LM. Peabody picture vocabulary test–third edition (PPVT-III) [database record]. APA PsycTests; 1997. doi: 10.1037/t15145-000
   Google Scholar
• Wong BY, Roadhouse A. The test of language development (TOLD): a validation study. Learn Disabil Quarterly. 1978;1(3):48–61. doi:10.2307/1510937
   Web of Science ®Google Scholar
• Frankenburg WK, Camp BW, Van Natta PA. Validity of the Denver developmental screening test. Child Dev. 1971;42(2):475–485. doi: 10.2307/1127481
   Web of Science ®Google Scholar
• Leiter RG, Arthur G. The Leiter international performance scale. Vol. 1. California: Santa Barbara State College Press; 1940.
   Google Scholar
• Marteleto MRF, Pedromônico MRM. Validity of autism behavior checklist (ABC): preliminary study. Rev Bras Psiquiatr. 2005;27(4):295–301. doi: 10.1590/S1516-44462005000400008
   PubMed Web of Science ®Google Scholar
• Krug DA, Arick JR, Almond PJ. ASIEP: autism screening instrument for educational planning, Revised. Austin, TX: Pro-Ed; 1980.
   Google Scholar
• Schopler E, Reichler RJ, DeVellis RF, et al. Toward objective classification of childhood autism: childhood autism rating scale (CARS). J Autism Dev Disord. 1980;10(1):91–103. doi: 10.1007/BF02408436
   PubMed Web of Science ®Google Scholar
• Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet A. 1988;30(1‐2):377–392. doi:10.1002/ajmg.1320300138
   Web of Science ®Google Scholar
• Conners CK, Sitarenios G, Parker JD, et al. Revision and restandardization of the Conners teacher rating scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):279–291. doi: 10.1023/A:1022606501530
   PubMed Web of Science ®Google Scholar
• Ullmann RK, Sleator EK, Sprague RL. A new rating scale for diagnosis and monitoring of ADD children. Psychopharmacol Bull. 1984;20(1):160–164.
   PubMedGoogle Scholar
• Strom CM, Brusca RM, Pizzi WJ. Double‐blind, placebo‐controlled crossover study of folinic acid (Leucovorin®) for the treatment of fragile X syndrome. Am J Med Genet A. 1992;44(5):676–682. doi:10.1002/ajmg.1320440529
   Web of Science ®Google Scholar
• Sparow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales. 2nd (VinelandTM-II) ed. Circle Pines: American Guidance Service; 2005.
   Google Scholar
• Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16(5):525–540. doi: 10.1089/cap.2006.16.525
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville, Maryland: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
   Google Scholar
• Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168–179. doi: 10.1097/00004583-200102000-00011
   PubMed Web of Science ®Google Scholar
• Torrioli MG, Vernacotola S, Peruzzi L, et al. A double‐blind, parallel, multicenter comparison of L‐acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146(7):803–812. doi: 10.1002/ajmg.a.32268
   Google Scholar
• Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–150. doi: 10.5664/jcsm.27443
   PubMed Web of Science ®Google Scholar
• Sahu JK, Gulati S, Sapra S, et al. Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. J Child Neurol. 2013;28(5):570–575. doi: 10.1177/0883073812449381
   PubMed Web of Science ®Google Scholar
• Leigh MJS, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34(3):147. doi: 10.1097/DBP.0b013e318287cd17
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Des Portes V, Hagerman R, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci, trans med. 2016;8(321):ra3215–ra3215. doi: 10.1126/scitranslmed.aab4109
   Web of Science ®Google Scholar
• Aman MG, Singh NN, Stewart AW, et al. Psychometric characteristics of the aberrant behavior checklist. Am J Mental Defic. 1985;89(5):492–502.
   PubMedGoogle Scholar
• Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377–1392. doi: 10.1007/s10803-011-1370-2
   PubMed Web of Science ®Google Scholar
• Hess LG, Fitzpatrick SE, Nguyen DV, et al. A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr. 2016;37(8):619. doi: 10.1097/DBP.0000000000000334
   PubMed Web of Science ®Google Scholar
• Mullen EM. Mullen scales of early learning. Circle Pines (MN): AGS; 1995. p. 58–64.
   Google Scholar
• Berry-Kravis E, Hagerman R, Visootsak J, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodevelop Disord. 2017;9(1):1–18. doi: 10.1186/s11689-016-9181-6
   PubMedGoogle Scholar
• Youssef EA, Berry-Kravis E, Czech C, et al. Effect of the mGlur5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results. Neuropsychopharmacology. 2018;43(3):503–512. doi: 10.1038/npp.2017.177
   PubMed Web of Science ®Google Scholar
• Esbensen AJ, Rojahn J, Aman MG, et al. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33(6):617–629. doi: 10.1023/B:JADD.0000005999.27178.55
   PubMed Web of Science ®Google Scholar
• Bruno JL, Hosseini SH, Lightbody AA, et al. Brain circuitry, behavior, and cognition: a randomized placebo-controlled trial of donepezil in fragile X syndrome. J Psychopharmacol. 2019;33(8):975–985. doi: 10.1177/0269881119858304
   PubMed Web of Science ®Google Scholar
• Anderson P, Anderson V, Northam E, et al. Standardization of theContingency Naming Test for school-aged children: A new measure of reactiveflexibility. Clinical Neuropsychological Assessment. 2000;1:247–273.
   Google Scholar
• Berry-Kravis E, Horrigan JP, Tartaglia N, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome. Pediatr Neurol. 2020;110:30–41. doi: 10.1016/j.pediatrneurol.2020.04.019
   PubMed Web of Science ®Google Scholar
• Berry-Kravis EM, Harnett MD, Reines SA, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nature Med. 2021;27(5):862–870. doi: 10.1038/s41591-021-01321-w
   PubMed Web of Science ®Google Scholar
• Akshoomoff N, Beaumont J, Bauer L, et al. National Institutes of Health Toolbox Cognition Battery (NIH Toolbox CB): validation for children between 3 and 15 years: VIII. NIH Toolbox Cognition Battery (CB): composite scores of crystallized, fluid, and overall cognition. Monogr Soc Res Child Dev. 2013;78(4):119–132.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hagerman R, Budimirovic D, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord. 2022;14(1):56. doi: 10.1186/s11689-022-09466-6
   PubMed Web of Science ®Google Scholar
• Torrioli MG, Vernacotola S, Mariotti P, et al. Double‐blind, placebo‐controlled study of L‐acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet A. 1999;87(4):366–368. doi: 10.1002/(SICI)1096-8628(19991203)87:4<366:AID-AJMG18>3.0.CO;2-F
   Web of Science ®Google Scholar
• Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins, Leukot Essent Fat Acids. 2002;67(1):33–38. doi:10.1054/plef.2002.0378
   PubMed Web of Science ®Google Scholar
• D’Antuono M, Merlo D, Avoli M. Involvement of cholinergic and GABAergic systems in the fragile X knockout mice. Neuroscience. 2003;119(1):9–13. doi:10.1016/S0306-4522(03)00103-9
   PubMed Web of Science ®Google Scholar
• Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J Med Genet. 2009;46(2):94–102. doi: 10.1136/jmg.2008.061796
   PubMed Web of Science ®Google Scholar
• Huber KM, Gallagher SM, Warren ST, et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Nat Acad Sci. 2002;99(11):7746–7750. doi:10.1073/pnas.122205699
   PubMed Web of Science ®Google Scholar
• Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Trans Med. 2012;4(152):ra152127–ra152127. doi: 10.1126/scitranslmed.3004214
   Web of Science ®Google Scholar
• Deacon RM, Glass L, Snape M, et al. NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromol Med. 2015;17(1):71–82. doi: 10.1007/s12017-015-8341-2
   PubMed Web of Science ®Google Scholar
• Heussler H, Cohen J, Silove N, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodevelop Disord. 2019;11(1):1–9. doi: 10.1186/s11689-019-9277-x
   PubMedGoogle Scholar
• Rueda JR, Ballesteros J, Tejada MI. Systematic review of pharmacological treatments in fragile X syndrome. BMC neurol. 2009;9(1):1–11. doi: 10.1186/1471-2377-9-53
   PubMedGoogle Scholar
• Budimirović DB, Duy PQ. Neurobehavioral features and targeted treatments in fragile X syndrome: Current insights and future directions. Engrami. 2015;37(4):5–26. doi:10.5937/engrami1504005B
   Google Scholar
• Ligsay A, Hagerman RJ. Review of targeted treatments in fragile X syndrome. Intractable Rare Dis. 2016;5(3):158–167.
   PubMedGoogle Scholar
• Budimirovic DB, Berry-Kravis E, Erickson CA, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017;9(1):1–36. doi: 10.1186/s11689-017-9193-x
   PubMedGoogle Scholar
• Berry-Kravis EM, Lindemann L, Jønch AE, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2018;17(4):280–299. doi: 10.1038/nrd.2017.221
   PubMed Web of Science ®Google Scholar
• Ligsay A, Van Dijck A, Nguyen DV, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord. 2017;9(1):1–13. doi: 10.1186/s11689-017-9207-8
   PubMedGoogle Scholar
• Watkins LV, O’Dwyer M, Shankar R. A review of the pharmacotherapeutic considerations for managing epilepsy in people with autism. Expert Opin Pharmacother. 2022;23(7):841–851. doi:10.1080/14656566.2022.2055461
   PubMed Web of Science ®Google Scholar
• Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021;22(4):209–222. doi:10.1038/s41583-021-00432-0
   PubMed Web of Science ®Google Scholar
• Hipp HS, Charen KH, Spencer JB, et al. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). Menopause. 2016;23(9):993–9. doi: 10.1097/GME.0000000000000658
   PubMed Web of Science ®Google Scholar
• Shah S, Sharp KJ, Raju Ponny S, et al. Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc Natl Acad Sci U S A. 2023;120(27):e2302534120. doi: 10.1073/pnas.2302534120
   PubMed Web of Science ®Google Scholar
• Bourgeois JA. Neuropsychiatry of fragile X-premutation carriers with and without fragile X-associated tremor-ataxia syndrome: implications for neuropsychology. Clin Neuropsychol. 2016;30(6):913–928. doi:10.1080/13854046.2016.1192134
   PubMed Web of Science ®Google Scholar
• Li N, Zhou T, Fei E. Actions of metformin in the brain: a new perspective of metformin treatments in related neurological disorders. Int J Mol Sci. 2022;23(15):8281.2022. doi:10.3390/ijms23158281
   Web of Science ®Google Scholar
• Miranda I, Hagerman R. Molecular mechanisms for targeted treatments in fragile X syndrome. Rare Dis Orphan Drugs J. 2023;2:20. doi: 10.20517/rdodj.2023.21
   Google Scholar
• Dy ABC, Tassone F, Eldeeb M, et al. Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2018;93(2):216–222. doi: 10.1111/cge.13039
   PubMed Web of Science ®Google Scholar
• Sherman SL, Kidd SA, Riley C, et al. FORWARD: a registry and longitudinal clinical database to study fragile X syndrome. Pediatrics. 2016;139(Suppl 3):S183–S193. doi:10.1542/peds.2016-1159E
   Google Scholar
• Hessl D, Sansone SM, Berry-Kravis E, et al. The NIH toolbox cognitive battery for intellectual disabilities: three preliminary studies and future directions. J Neurodev Disord. 2016;8(1):35. doi: 10.1186/s11689-016-9167-4
   PubMedGoogle Scholar